Memory-related process in physiological status and alzheimer’s disease

Fotuhi, Seyedeh Nahid; Khalaj‐Kondori, Mohammad; Feizi, Mohammad Ali Hoseinpour; Talebi, Mahnaz

doi:10.1007/s11033-020-05438-y

Cited by 13 publications

(7 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) has reported that around 55 million people have dementia, and there are about 10 million new cases each year [2]. AD is distinguished by amyloid β (Aβ) plaques and intraneuronal deposition of neuro brillary tangles (NFTs) [3,4]. Clinically, AD starts with impairment in short-term memory, language disturbance, and inability to perform usual activities.…”

Section: Introductionmentioning

confidence: 99%

Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer’s disease

2022

View full text Add to dashboard Cite

Alzheimer's disease (AD) is one of the most important known dementia which affects thousands of people every year. Many factors are involved in this process, such as aberrant expression of miRNAs. Firstly, we analyzed two microarray datasets related to AD (GSE48552, GSE129053) to identify the differentially expressed miRNAs, and two miRNAs were selected for further validation. Dataset analysis showed that the expression of hsa-miR200a-3p and hsa-miR502-3p were up-regulated in AD. These ndings were validated in plasma samples by qRT-PCR. ROC curve analysis showed that plasma levels of both miRNAs might discriminate the AD and healthy controls. In addition, in silico analysis revealed that the upregulation of these miRNAs could promote AD progression via affecting the expression of target molecules mainly ATF6 and dynactin. Totally, hsa-miR200a-3p and hsa-miR502-3p are upregulated in AD and their plasma levels can discriminate AD and healthy people, highlighting their potential as bloodbased biomarker for AD.Informed consent: Informed consent was obtained from all individuals that gave their blood samples for including in the study.

show abstract

Section: Introductionmentioning

confidence: 99%

Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer’s disease

2022

View full text Add to dashboard Cite

show abstract

“…According to the electrophysiological findings of a previous study, LTP was compromised in the experimental group [ 54 ]. The hippocampus is the locus of synaptic plasticity and a critical location for the pathological alterations associated with AD [ 55 ]. Synaptic Ca 2+ influx in hippocampal pyramidal neurons is decreased by Aβ oligomers, which accelerate neuronal cell death [ 56 ] and affect neuronal synaptic plasticity by reducing dendritic spine density in the hippocampus and impairing cognitive function in AD patients [ 57 ].…”

Section: Neurotransmitter Abnormalities and Cognitive Dysfunctionmentioning

confidence: 99%

Neurotransmitters in Prevention and Treatment of Alzheimer’s Disease

Yang

Zou

Wang

2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most frequent cause of cognitive impairment in middle-aged and older populations. There is a lack of drugs that demonstrate significant efficacy in AD, so the study of the pathogenesis of AD is of great importance. More efficacious interventions are needed, as reflected by our population’s fast aging. Synaptic plasticity is the capacity of neurons to adjust their connections, and it is strongly tied to learning and memory, cognitive function, and brain injury recovery. Changes in synaptic strength, such as long-term potentiation (LTP) or inhibition (LTD), are thought to represent the biological foundation of the early stages of learning and memory. The results of numerous studies confirm that neurotransmitters and their receptors play an important role in the regulation of synaptic plasticity. However, so far, there is no definite correlation between the function of neurotransmitters in aberrant neural oscillation and AD-related cognitive impairment. We summarized the AD process to understand the impact of neurotransmitters in the progression and pathogenesis of AD, including the current status of neurotransmitter target drugs, and the latest evidence of neurotransmitters’ function and changes in the AD process.

show abstract

“…Individuals with AD usually undergo difficulties in learning, performance speed, recall accuracy, and problem-solving [ 86 ]. Hippocampal involvement in AD pathogenesis is evident from a wide range of clinical and preclinical studies [ 82 , 87 , 88 , 89 , 90 , 91 ]. In AD, the hippocampal cornu ammonis (CA) 1 subregion is the first target of pathological hallmarks (i.e., NFTs), followed by the subiculum, CA2, CA3, and dentate gyrus (DG) [ 92 , 93 , 94 ].…”

Section: Hippocampal Dysfunction In Neurodegenerative Diseasesmentioning

confidence: 99%

Structural Plasticity of the Hippocampus in Neurodegenerative Diseases

Weerasinghe-Mudiyanselage

Ang

Kang

et al. 2022

IJMS

View full text Add to dashboard Cite

Neuroplasticity is the capacity of neural networks in the brain to alter through development and rearrangement. It can be classified as structural and functional plasticity. The hippocampus is more susceptible to neuroplasticity as compared to other brain regions. Structural modifications in the hippocampus underpin several neurodegenerative diseases that exhibit cognitive and emotional dysregulation. This article reviews the findings of several preclinical and clinical studies about the role of structural plasticity in the hippocampus in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis. In this study, literature was surveyed using Google Scholar, PubMed, Web of Science, and Scopus, to review the mechanisms that underlie the alterations in the structural plasticity of the hippocampus in neurodegenerative diseases. This review summarizes the role of structural plasticity in the hippocampus for the etiopathogenesis of neurodegenerative diseases and identifies the current focus and gaps in knowledge about hippocampal dysfunctions. Ultimately, this information will be useful to propel future mechanistic and therapeutic research in neurodegenerative diseases.

show abstract

Memory-related process in physiological status and alzheimer’s disease

Cited by 13 publications

References 79 publications

Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer’s disease

Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer’s disease

Neurotransmitters in Prevention and Treatment of Alzheimer’s Disease

Structural Plasticity of the Hippocampus in Neurodegenerative Diseases

Contact Info

Product

Resources

About